There are other documents more specific to HRPC in general, but it would take me a while to find. There was a FDA Prostate Cancer Workshop pre-Impact results (and follow-up publication shortly post Impact results) discussing the suitability of various endpoints in HRPC. It has been a long while since I looked at this stuff. They better have a SPA for the P3 as Pazdur wants survival as the primary.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.